Reaction Details |
| Report a problem with these data |
Target | Coagulation factor X |
---|
Ligand | BDBM50144129 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEBML_48628 |
---|
IC50 | >11000±n/a nM |
---|
Citation | Jia, ZJ; Su, T; Zuckett, JF; Wu, Y; Goldman, EA; Li, W; Zhang, P; Clizbe, LA; Song, Y; Bauer, SM; Huang, W; Woolfrey, J; Sinha, U; Arfsten, AE; Hutchaleelaha, A; Hollenbach, SJ; Lambing, JL; Scarborough, RM; Zhu, BY N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors. Bioorg Med Chem Lett14:2073-8 (2004) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Coagulation factor X |
---|
Name: | Coagulation factor X |
Synonyms: | Activated coagulation factor X (FXa) | Activated factor Xa heavy chain | Coagulation factor X precursor | Coagulation factor Xa | F10 | FA10_HUMAN | Factor X heavy chain | Factor X light chain | Factor Xa | Stuart factor | Stuart-Prower factor |
Type: | Enzyme |
Mol. Mass.: | 54726.60 |
Organism: | Homo sapiens (Human) |
Description: | n/a |
Residue: | 488 |
Sequence: | MGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEE
TCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKN
CELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERR
KRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQE
CKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGE
AVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGI
VSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSG
GPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPE
VITSSPLK
|
|
|
BDBM50144129 |
---|
n/a |
---|
Name | BDBM50144129 |
Synonyms: | CHEMBL64947 | [4-(5-Chloro-1H-indole-2-carbonyl)-piperazin-1-yl]-[4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)-phenyl]-methanone |
Type | Small organic molecule |
Emp. Form. | C24H24ClN5O2 |
Mol. Mass. | 449.933 |
SMILES | CN1CCN=C1c1ccc(cc1)C(=O)N1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1 |c:4| |
Structure |
|